We are excited to be working on cutting-edge medicinal applications in the field of gerontology. In anticipation of having successful products we continue to look for major cosmetics firms interested in
Sacramento, CA (PRWEB) January 18, 2006
Telomolecular Corporation has announced plans to develop and release a line of cosmetic products that efficiently treat degraded chromosomal telomeres in skin and fibroblast tissues by March 30th of 2007. Repairing degraded telomeres in these cells is expected to rejuvenate even very old skin to a “young state”. Telomere therapy based on Telomolecular nanotechnologies may represent the first step in rejuvenating human beings and extending their lifespans considerably. Treatment with “telomerizing” agents may correct a variety of devastating and presently incurable age-related diseases such as macular degeneration, atherosclerosis, arteriosclerosis, liver cirrhosis, and other degenerative disorders caused by telomere shortening. Initial feasibility studies indicate the product will be safe and is likely to work successfully in vivo.
The effect of telomerase in various cell types has been studied. Dr. Shay and Dr. Wright and colleagues at Southwestern Medical Center found that adding the gene that encodes human telomerase reverse transcriptase (TERT) into telomerase-negative human retina and foreskin cells caused the expression of telomerase. Telomeres elongated, and the cells divided vigorously and did not express a cell marker for senescence (beta galactosidase). Furthermore, the cells showed an increased number of cell divisions and a limitless life span, compared to cells that were not treated with telomerase, whose telomeres shortened with each division, leading to senescence. Another important observation was that the introduction of telomerase into the cells and their continuous rapid division and longer life span did not make them cancerous. They remained with a young appearance and normal number of chromosomes. Telomolecular was formed to develop practical ways to apply these discoveries in vivo.
According to Matthew A. Sarad, Chief Executive Officer of Telomolecular, “We are excited to be working on cutting-edge medicinal applications in the field of gerontology. In anticipation of having successful products we continue to look for major cosmetics firms interested in “commercializing” and “distributing” our goods. We think it is important that cosmetic companies begin to think about the immediate prospects and impact of telomere therapy in their industry, since in less than a decade those companies that rely heavily on skin crème products, and who are slow to react to the opportunity of biomedical rejuvenation, are likely to find that they no longer have a market for their products.”
Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. Telomolecular’s nanotechnologies work in living animals and have been used to deliver a wide variety of therapeutic large-molecules that were previously considered too large and complex to deliver intracellularly through traditional gene therapies. These large-molecules can be delivered in a comprehensive, safe, and inexpensive manner this is far superior to delivery by viruses, liposomes, or viral components. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs we recognize as human aging.
Telomolecular Investor Relations
Mr. Matthew A. Sarad